Abstract

Aim. To assess the levels of s BGP and BAP and correlate them with the rate of bone remodelling. Patients and Methods. The study was performed on 74 cases with postmenopausal osteoporosis, divided into two groups, according to the duration of estrogenic deprivation, compared with a control group (n= 20, postmenopausal women without osteoporosis). The serum levels of the discussed markers were measured by ELISA technique. BMD was measured using the DXA technique with the assessment of T score. Results. In the group I: BGP were 20.12±0.87ng/mL (p<0.03), those of BAP 13.76±0.6μg/mL (p<0.001) and sT spine were -3.63±0.65DS (p<0.001). In the group II: BGP were 15.12±1.55ng/mL (p<0.05), those of BAP 11.88±0.38μg/mL (p<0.001) and sT spine were -3.78±0.36DS (p<0.001). The control group presented: BGP of 16.22±1.62ng/mL, those of BAP of 8.68±0.44μg/mL and sT spine of -1.78±0.11DS. The serum levels of BGP in postmenopausal osteoporosis cases were increased in group I (suggesting an osteoblastic activation) and decreased in group II (probably secondary to the stimulation of osteoblastic apoptosis). The serum levels of BAP are significantly increased in postmenopausal osteoporosis versus control group, attesting osteoblastic activation. Conclusion. Bone resorption begins gradually to outrun a new bone formation rhythm associated with low BMD.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call